COVID-19-Induced Actemra Shortage Causes Headaches For CAR-T Centers

Some Hematologists Report Having Problems Scheduling Cell Therapy

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

While some cancer centers report sufficient stocks of the drug, they have already been turning to potential alternatives due to supply issues that could last for weeks or months.  

3D illustration of T cells attacking a cancer cell (CAR-T cell therapy) - Illustration
• Source: Shutterstock

As the recent COVID-19 surge has overfilled intensive care units and emergency rooms, it is also creating growing problems for cancer centers. The demand for Roche Holding AG’s Actemra (tocilizumab) to treat severely ill COVID-19 patients has caused a shortage of the drug, leaving less supply for patients receiving chimeric antigen receptor T-cell (CAR-T) therapies.

Roche’s Genentech division said 16 August that the large increase in hospitalizations for severe COVID-19 had caused a shortage of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from COVID-19

New COVID-19 Vaccines Shipping Soon, After Rapid Pivot To Address New Strain

 
• By Alaric DeArment

Pfizer/BioNTech and Moderna rapidly adapted Comirnaty and Spikevax for the 2024-2025 season to address the KP.2 variant after the US FDA had advised them to target JN.1 in June.

Pfizer/BioNTech Combo Vaccine Shows Partial Flu Efficacy

 
• By Alaric DeArment

The companies said their combination mRNA vaccine showed protection against SARS-CoV-2 and influenza A, but not influenza B.

AstraZeneca Moves To Join Invyvid In COVID-19 Prevention

 
• By Elizabeth Cairns

The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.    

Stock Watch: Thoroughly Moderna Missteps

 
• By Andy Smith

When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains